Clinical bottom line
Selection of biologic and small-molecule therapies in inflammatory bowel disease (IBD) requires individualized assessment of efficacy, safety, and patient factors. Recent network meta-analyses demonstrate varying comparative effectiveness among agents for ulcerative colitis, while dual therapy with biologics or small molecules emerges as a potential option for refractory disease. Therapeutic drug monitoring (TDM) enhances optimization of treatment regimens. Despite advances, treatment decisions remain complex due to heterogeneity in patient response and limited head-to-head data (Shehab et al., 2025; Fudman et al., 2025).
What the evidence shows
Shehab et al. (2025) performed a systematic review and network meta-analysis comparing biologics and small molecules in ulcerative colitis, finding that anti-TNF agents, vedolizumab, ustekinumab, and Janus kinase (JAK) inhibitors differ in efficacy and safety profiles. JAK inhibitors showed rapid induction of remission but with safety considerations, while vedolizumab had a favorable safety profile but slower onset.
Fudman et al. (2025) provide practical guidance on positioning advanced therapies, emphasizing patient-specific factors such as disease severity, comorbidities, and prior treatment exposure. They highlight the importance of integrating clinical, endoscopic, and biomarker data to guide therapy choice.
Ahmed et al. (2022) and related meta-analyses explore dual biologic or small-molecule therapy for refractory IBD, reporting promising efficacy in patients failing monotherapy, albeit with limited safety data and potential increased infection risk.
Therapeutic drug monitoring is increasingly recognized as essential for optimizing biologic and small-molecule dosing, as detailed by Dutt et al. (2024), improving response rates and minimizing adverse effects.
Pediatric data (Geem et al., 2020; Dolinger et al., 2020) support cautious use of dual therapy in treatment-refractory cases, underscoring the need for close monitoring.
Caveats and uncertainty
Most comparative data derive from indirect comparisons; few head-to-head randomized trials exist.
Long-term safety and cost-effectiveness of dual therapy remain uncertain.
Heterogeneity in study populations and endpoints complicate generalizability.
Optimal sequencing and combination strategies are not yet standardized.
TDM availability and interpretation vary across clinical settings.
How this may change practice
Clinicians should individualize biologic and small-molecule selection based on disease phenotype, prior therapy, and patient preferences, informed by emerging comparative efficacy data.
Dual therapy may be considered for refractory patients after careful risk-benefit assessment and in specialized centers.
Routine incorporation of therapeutic drug monitoring can enhance treatment optimization.
Multidisciplinary collaboration and patient education are critical to navigate complex treatment landscapes.
Ongoing research and guideline updates will refine evidence-based algorithms for therapy selection.